全文获取类型
收费全文 | 261245篇 |
免费 | 66361篇 |
国内免费 | 2766篇 |
专业分类
耳鼻咽喉 | 6312篇 |
儿科学 | 9793篇 |
妇产科学 | 4107篇 |
基础医学 | 23309篇 |
口腔科学 | 8207篇 |
临床医学 | 40108篇 |
内科学 | 78386篇 |
皮肤病学 | 14804篇 |
神经病学 | 29166篇 |
特种医学 | 9125篇 |
外科学 | 59253篇 |
综合类 | 407篇 |
现状与发展 | 72篇 |
一般理论 | 30篇 |
预防医学 | 12920篇 |
眼科学 | 5089篇 |
药学 | 8696篇 |
中国医学 | 1131篇 |
肿瘤学 | 19457篇 |
出版年
2024年 | 714篇 |
2023年 | 5064篇 |
2022年 | 1991篇 |
2021年 | 5693篇 |
2020年 | 11679篇 |
2019年 | 13827篇 |
2018年 | 17000篇 |
2017年 | 17793篇 |
2016年 | 19353篇 |
2015年 | 19543篇 |
2014年 | 26936篇 |
2013年 | 28195篇 |
2012年 | 12310篇 |
2011年 | 12373篇 |
2010年 | 19768篇 |
2009年 | 19984篇 |
2008年 | 10301篇 |
2007年 | 7814篇 |
2006年 | 10122篇 |
2005年 | 7156篇 |
2004年 | 6165篇 |
2003年 | 4877篇 |
2002年 | 4795篇 |
2001年 | 4807篇 |
2000年 | 3872篇 |
1999年 | 3739篇 |
1998年 | 4014篇 |
1997年 | 3760篇 |
1996年 | 3623篇 |
1995年 | 3480篇 |
1994年 | 2158篇 |
1993年 | 1721篇 |
1992年 | 1537篇 |
1991年 | 1527篇 |
1990年 | 1174篇 |
1989年 | 1272篇 |
1988年 | 1083篇 |
1987年 | 919篇 |
1986年 | 967篇 |
1985年 | 796篇 |
1984年 | 626篇 |
1983年 | 591篇 |
1982年 | 604篇 |
1981年 | 468篇 |
1980年 | 436篇 |
1979年 | 361篇 |
1978年 | 378篇 |
1977年 | 438篇 |
1975年 | 313篇 |
1972年 | 316篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves
a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because
of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address
issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment
should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these
are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating
a successful pharmacologic treatment program for patients with fibromyalgia. 相似文献
22.
23.
24.
Zinc sulfate addition to glass-ionomer-based cements: influence on physical and antibacterial properties, zinc and fluoride release. 总被引:5,自引:0,他引:5
Prudencio W R Osinaga Rosa Helena M Grande Rafael Y Ballester Maria Regina L Simionato Célia Regina M Delgado Rodrigues Antonio Muench 《Dental materials》2003,19(3):212-217
OBJECTIVES: The aim of this study is to evaluate the effect of ZnSO(4) addition to a conventional glass ionomer and a resin-modified glass ionomer on solubility, flexural strength, zinc and fluoride (F) release, and Streptococcus mutans growth inhibition. METHODS: 5 or 10% ZnSO(4) was added to Vitremer and Ketac-Fil powders. Solubility test was performed based on ISO 7489. Flexural strength was determined by 3-point bending test based on ISO 4049. Zn release/uptake was determined by atomic emission spectrometry; F release/uptake was measured using a F-specific electrode. Both release measurements were performed for 15 d before and 15 d after recharging. Antibacterial test was conducted according to agar plate methods against S. mutans, by measuring the inhibition halos in 1-h and 15-d specimens. Data were analyzed by ANOVA. RESULTS: Solubility increased with higher ZnSO(4) content, but remained below the ISO 7489 limit. Flexural strength was not affected by ZnSO(4) addition, and Vitremer performed better than Ketac-Fil. The control materials released no zinc. Vitremer with 10% ZnSO(4) released the highest amount of zinc. Fluoride release was similar for Ketac-Fil and Vitremer. In both cases, the highest amounts were released in the first 24 h. The growth inhibition halo of S. mutans was similar for both materials with highest content of ZnSO(4) and occurred only with 1-h specimens. SIGNIFICANCE: Zinc addition decreased microorganisms growth and improved fluoride release, without significantly affecting the materials' flexural strength and solubility. 相似文献
25.
26.
27.
We report clinical, neuroradiologic features, and neuropathologic findings of a 76‐year‐old man with coexistent Pick’s disease and progressive supranuclear palsy. The patient presented with loss of recent memory, abnormal behavior and change in personality at the age of 60. The symptoms were progressive. Three years later, repetitive or compulsive behavior became prominent. About 9 years after onset, he had difficulty moving and became bed‐ridden because of a fracture of his left leg. His condition gradually deteriorated and he developed mutism and became vegetative. The patient died from pneumonia 16 years after the onset of symptoms. Serial MRI scans showed progressive cortex atrophy, especially in the bilateral frontal and temporal lobes. Macroscopic inspection showed severe atrophy of the whole brain, including cerebrum, brainstem and cerebellum. Microscopic observations showed extensive superficial spongiosis and severe neuronal loss with gliosis in the second and third cortical layers in the frontal, temporal and parietal cortex. There were Pick cells and argyrophilic Pick bodies, which were tau‐ and ubiquitin‐positive in neurons of layers II–III of the above‐mentioned cortex. Numerous argyrophilic Pick bodies were observed in the hippocampus, especially in the dentate fascia. In addition, moderate to severe loss of neurons was found with gliosis and a lot of Gallyas/tau‐positive globus neurofibrillary tangles in the caudate nucleus, globus pallidus, thalamus, substantia nigra, locus coeruleus and dentate nucleus. Numerous thorned‐astrocytes and coiled bodies but no‐tuft shaped astrocytes were noted in the basal ganglion, brainstem and cerebellar white matter. In conclusion, these histopathological features were compatible with classical Pick’s disease and coexistence with progressive supranuclear palsy without tuft‐shaped astrocytes. 相似文献
28.
29.
30.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献